Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Sell
28
RCKT Quote, Financials, Valuation and Earnings
Last price:
$7.23
Seasonality move
:
0.93%
Day range:
$7.11 - $7.50
52-week range:
$4.55 - $26.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.71x
Volume:
2.3M
Avg. volume:
3.4M
1-year change:
-68.56%
Market cap:
$792.3M
Revenue:
--
EPS (TTM):
-$2.73
Analysts' Opinion
-
Consensus RatingRocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $40.27, Rocket Pharmaceuticals has an estimated upside of 441.95% from its current price of $7.43.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing -290.31% downside risk from its current price of $7.43.
Fair Value
-
According to the consensus of 13 analysts, Rocket Pharmaceuticals has 441.95% upside to fair value with a price target of $40.27 per share.
RCKT vs. S&P 500
-
Over the past 5 trading days, Rocket Pharmaceuticals has overperformed the S&P 500 by 16.36% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rocket Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rocket Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rocket Pharmaceuticals reported revenues of --.
Earnings Growth
-
Rocket Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rocket Pharmaceuticals reported earnings per share of -$0.62.
Enterprise value:
419.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$223.8M | -$259.7M | -$273.2M | -$63.3M | -$62.7M | |
| EBITDA | -$213.7M | -$236.6M | -$247.5M | -$57.3M | -$57.5M | |
| Diluted EPS | -$3.26 | -$2.94 | -$2.73 | -$0.64 | -$0.62 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $487.3M | $392.1M | $364.1M | $378.2M | $378.2M | |
| Total Assets | $590.8M | $497M | $551.8M | $566.3M | $527.7M | |
| Current Liabilities | $32.6M | $22.2M | $39.2M | $48.5M | $40.7M | |
| Total Liabilities | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | |
| Total Equity | $503.5M | $454.7M | $489.7M | $492.6M | $463.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$178.1M | -$194.9M | -$209.7M | -$29.3M | -$46.9M | |
| Cash From Investing | -$69.3M | -$98.1M | $131.7M | -$140.8M | -$37.9M | |
| Cash From Financing | $155.3M | $208.4M | $185.7M | $391K | $182.8M | |
| Free Cash Flow | -$186.8M | -$211.4M | -$215.6M | -$34M | -$47.3M | |
RCKT
Sector
Market Cap
$792.3M
$36.4M
Price % of 52-Week High
27.54%
44.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-68.56%
-39.12%
Beta (5-Year)
1.000
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.70
200-day SMA
Sell
Level
$14.46
Bollinger Bands (100)
Sell
Level
7.5 - 12.44
Chaikin Money Flow
Sell
Level
-37.4M
20-day SMA
Buy
Level
$6.21
Relative Strength Index (RSI14)
Buy
Level
54.89
ADX Line
Buy
Level
34.33
Williams %R
Sell
Level
-2.3729
50-day SMA
Sell
Level
$8.02
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
96.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Stock Forecast FAQ
In the current month, RCKT has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RCKT average analyst price target in the past 3 months is $40.27.
-
Where Will Rocket Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rocket Pharmaceuticals share price will rise to $40.27 per share over the next 12 months.
-
What Do Analysts Say About Rocket Pharmaceuticals?
Analysts are divided on their view about Rocket Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rocket Pharmaceuticals is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is Rocket Pharmaceuticals's Price Target?
The price target for Rocket Pharmaceuticals over the next 1-year time period is forecast to be $40.27 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RCKT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rocket Pharmaceuticals is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RCKT?
You can purchase shares of Rocket Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rocket Pharmaceuticals shares.
-
What Is The Rocket Pharmaceuticals Share Price Today?
Rocket Pharmaceuticals was last trading at $7.23 per share. This represents the most recent stock quote for Rocket Pharmaceuticals. Yesterday, Rocket Pharmaceuticals closed at $7.43 per share.
-
How To Buy Rocket Pharmaceuticals Stock Online?
In order to purchase Rocket Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 36x
Alerts
Sell
48
FI alert for Apr 25
Fiserv [FI] is up 0.33% over the past day.
Buy
66
FARO alert for Apr 25
Faro Technologies [FARO] is up 0.93% over the past day.
Buy
55
PI alert for Apr 25
Impinj [PI] is up 2.15% over the past day.
